Literature DB >> 27653570

Engineering Reversal - Finding an Antidote for Direct Oral Anticoagulants.

Beverley J Hunt1, Marcel Levi1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27653570     DOI： 10.1056/NEJMe1610510

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  [Comment on: Andexanet alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.]

Authors:  H Lier; O Grottke
Journal:  Anaesthesist       Date:  2016-12       Impact factor: 1.041

2.  Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis.

Authors:  Truman J Milling; Carol L Clark; Charles Feronti; Shlee S Song; Sam S Torbati; Gregory J Fermann; Jeffrey Weiss; Dony Patel
Journal:  Am J Emerg Med       Date:  2017-08-19       Impact factor: 2.469

3.  Spontaneous splenic rupture due to rivaroxaban.

Authors:  Vinayak Nagaraja; Greg Cranney; Virag Kushwaha
Journal:  BMJ Case Rep       Date:  2018-03-05

Review 4.  Direct oral anticoagulants: a review on the current role and scope of reversal agents.

Authors:  Rahul Chaudhary; Tushar Sharma; Jalaj Garg; Ajaypaul Sukhi; Kevin Bliden; Udaya Tantry; Mohit Turagam; Dhanunjaya Lakkireddy; Paul Gurbel
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

Review 5.  Reversing factor Xa inhibitors - clinical utility of andexanet alfa.

Authors:  Scott Kaatz; Hardik Bhansali; Joseph Gibbs; Robert Lavender; Charles E Mahan; David G Paje
Journal:  J Blood Med       Date:  2017-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.